-
141
-
142
Performance analysis of asymmetrical less‐rare‐earth permanent magnet motor for electric vehicle
Published 2022-03-01Get full text
Article -
143
-
144
An exploratory study of INPP4B, a biomarker of gemcitabine chemoresistance in pancreatic cancer
Published 2024-12-01Get full text
Article -
145
-
146
Microbial mechanisms underlying the reduction of N2O emissions from submerged plant covered system
Published 2025-09-01Get full text
Article -
147
Solid Self-Microemulsifying Drug Delivery System for Improved Oral Bioavailability of Relugolix: Preparation and Evaluation
Published 2025-01-01“…Zi-Lin Li,1,* Guo-Xing Deng,1,* Chuan-Zhou Fang,1,* Yue-Qi Zhao,1 Jing Yuan,2 Liang Chen,3 Hai-Jun Zhong,1 Feng Guo1 1School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 2College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, 471000, People’s Republic of China; 3Jiangxi Prozin Pharmaceutical Co., LTD, Jian, 343100, People’s Republic of China*These authors contributed equally to this workCorrespondence: Feng Guo; Hai-JunZhong, School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China, Tel +86 0791 86361839, Email fengguo@ncu.edu.cn; zhonghj@ncu.edu.cnPurpose: To improve the oral absorption of relugolix (RLGL), which has low oral bioavailability due to its low solubility and being a substrate of P-glycoprotein (P-gp). …”
Get full text
Article -
148
-
149
The Clinical Characteristics, Patterns of Recurrence, and Long-Term Survival Outcomes of Dual-Phenotype Hepatocellular Carcinoma After Curative Liver Resection
Published 2025-01-01“…Zi-Chen Yu,1,2 Zheng-Kang Fang,1,2 Yang Yu,3 Si-Yu Liu,4 Kai-Di Wang,1,5 Zhe-Jin Shi,1,5 Li-Ming Jin,1 Xiao-Kun Huang,1,2 Yi Lu,1 Guo-Liang Shen,1 Jun-Wei Liu,1 Dong-Sheng Huang,1 Cheng-Wu Zhang,1 Lei Liang1 1Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, General Surgery, Cancer Center, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China; 3Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China; 4Department of Laboratory Medicine, The Key Laboratory of Imaging Diagnosis and Minimally Invasive Interventional Research of Zhejiang Province, Zhejiang University Lishui Hospital, Lishui, Zhejiang, People’s Republic of China; 5Department of the second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence: Lei Liang, General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimal Invasive Surgery, Zhejiang Provincial People’s Hospital, Affiliated People’s Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People’s Republic of China, Email liangl1992@hotmail.comBackground & Aims: Dual-phenotype hepatocellular carcinoma (DPHCC) is discernible from classical HCC (CHCC) in its morphology and is characterized by the co-expression of both CHCC and cholangiocyte markers. …”
Get full text
Article